• Cenix BioScience Establishes Flanders R&D Subsidiary

News & Views

Cenix BioScience Establishes Flanders R&D Subsidiary

Cenix BioScience a leading contract research organisation specialising in RNA interference- (RNAi) and microRNA- (miRNA) -based drug discovery, is growing its R&D operations by establishing a new subsidiary in Flanders, Belgium.

Cenix BioScience BVBA, wholly owned by its Dresden-based parent, will help accelerate the company’s R&D capabilities in key growth areas including CNS-focused drug discovery and in vivo RNAi. This expansion comes as part of a major growth and diversification initiative ongoing since 2008 to broaden the company’s range of activities beyond the cell-based RNAi services that have established Cenix over the past 11 years.

“We are very excited to start this important new phase in our company’s development,” said Dr. Christophe Echeverri, CEO/CSO of Cenix. “This opportunity comes as the result of many years of hard work by past and present staff. It also arises at a particularly strategic time in the maturation of the RNAi field, which we are eager to help drive further forward in the years to come, now through both our original Dresden team and our new Flanders unit.”


Digital Edition

Lab Asia 31.6 Dec 2024

December 2024

Chromatography Articles - Sustainable chromatography: Embracing software for greener methods Mass Spectrometry & Spectroscopy Articles - Solving industry challenges for phosphorus containi...

View all digital editions

Events

Turkchem

Nov 27 2024 Istanbul, Turkey

Smart Factory Expo 2025

Jan 22 2025 Tokyo, Japan

Instrumentation Live

Jan 22 2025 Birmingham, UK

SLAS 2025

Jan 25 2025 San Diego, CA, USA

Arab Health

Jan 27 2025 Dubai, UAE

View all events